Historique
Article de Périodique
Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis (2020)
Auteur(s) :
CHENG, H. Y. ;
MCGUINNESS, L. A. ;
ELBERS, R. G. ;
MACARTHUR, G. J. ;
TAYLOR, A. ;
MCALEENAN, A. ;
DAWSON, S. ;
LOPEZ-LOPEZ, J. A. ;
HIGGINS, J. P. T. ;
COWLISHAW, S. ;
LINGFORD-HUGHES, A. ;
HICKMAN, M. ;
KESSLER, D.
Année
2020
Page(s) :
m3934
Sous-type de document :
Méta-analyse / Meta-analysis ; Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
59
Domaine :
Alcool / Alcohol
Thésaurus mots-clés
SOINS DE PREMIER RECOURS
;
ACCEPTABILITE
;
DESINTOXICATION
;
ALCOOL
;
INTERVENTION
;
TRAITEMENT
;
ABSTINENCE
;
EFFICACITE
;
ACAMPROSATE
;
OBSERVANCE DU TRAITEMENT
;
NALTREXONE
;
CURE DE DESINTOXICATION
Note générale :
Editorial: McCambridge J., Stewart D. Managing alcohol use in primary care. British Medical Journal, 2020, Vol. 371, n° 8270, m4129. https://doi.org/10.1136/bmj.m4129
Résumé :
Objective: To determine the most effective interventions in recently detoxified, alcohol dependent patients for implementation in primary care.
Design: Systematic review and network meta-analysis.
Data sources: Medline, Embase, PsycINFO, Cochrane CENTRAL, ClinicalTrials.gov, and the World Health Organization’s International Clinical Trials Registry Platform.
Study selection: Randomised controlled trials comparing two or more interventions that could be used in primary care. The population was patients with alcohol dependency diagnosed by standardised clinical tools and who became detoxified within four weeks.
Data extraction: Outcomes of interest were continuous abstinence from alcohol (effectiveness) and all cause dropouts (as a proxy for acceptability) at least 12 weeks after start of intervention.
Results: 64 trials (43 interventions) were included. The median probability of abstinence across placebo arms was 25%. Compared with placebo, the only intervention associated with increased probability of abstinence and moderate certainty evidence was acamprosate (odds ratio 1.86, 95% confidence interval 1.49 to 2.33, corresponding to an absolute probability of 38%). Of the 62 included trials that reported all cause dropouts, interventions associated with a reduced number of dropouts compared with placebo (probability 50%) and moderate certainty of evidence were acamprosate (0.73, 0.62 to 0.86; 42%), naltrexone (0.70, 0.50 to 0.98; 41%), and acamprosate-naltrexone (0.30, 0.13 to 0.67; 17%). Acamprosate was the only intervention associated with moderate confidence in the evidence of effectiveness and acceptability up to 12 months. It is uncertain whether other interventions can help maintain abstinence and reduce dropouts because of low confidence in the evidence.
Conclusions: Evidence is lacking for benefit from interventions that could be implemented in primary care settings for alcohol abstinence, other than for acamprosate. More evidence from high quality randomised controlled trials is needed, as are strategies using combined interventions (combinations of drug interventions or drug and psychosocial interventions) to improve treatment of alcohol dependency in primary care.
Systematic review registration: PROSPERO CRD42016049779.
Design: Systematic review and network meta-analysis.
Data sources: Medline, Embase, PsycINFO, Cochrane CENTRAL, ClinicalTrials.gov, and the World Health Organization’s International Clinical Trials Registry Platform.
Study selection: Randomised controlled trials comparing two or more interventions that could be used in primary care. The population was patients with alcohol dependency diagnosed by standardised clinical tools and who became detoxified within four weeks.
Data extraction: Outcomes of interest were continuous abstinence from alcohol (effectiveness) and all cause dropouts (as a proxy for acceptability) at least 12 weeks after start of intervention.
Results: 64 trials (43 interventions) were included. The median probability of abstinence across placebo arms was 25%. Compared with placebo, the only intervention associated with increased probability of abstinence and moderate certainty evidence was acamprosate (odds ratio 1.86, 95% confidence interval 1.49 to 2.33, corresponding to an absolute probability of 38%). Of the 62 included trials that reported all cause dropouts, interventions associated with a reduced number of dropouts compared with placebo (probability 50%) and moderate certainty of evidence were acamprosate (0.73, 0.62 to 0.86; 42%), naltrexone (0.70, 0.50 to 0.98; 41%), and acamprosate-naltrexone (0.30, 0.13 to 0.67; 17%). Acamprosate was the only intervention associated with moderate confidence in the evidence of effectiveness and acceptability up to 12 months. It is uncertain whether other interventions can help maintain abstinence and reduce dropouts because of low confidence in the evidence.
Conclusions: Evidence is lacking for benefit from interventions that could be implemented in primary care settings for alcohol abstinence, other than for acamprosate. More evidence from high quality randomised controlled trials is needed, as are strategies using combined interventions (combinations of drug interventions or drug and psychosocial interventions) to improve treatment of alcohol dependency in primary care.
Systematic review registration: PROSPERO CRD42016049779.
Affiliation :
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK